Jazz Pharma Plc (JAZZ)
$134.83 3.44 (2.62%)
17:30 EDT JAZZ Stock Quote Delayed 15 Minutes
Previous Close $134.83
Market Cap 7.81B
PE Ratio 18.47
Volume (Avg. Vol.) 246,100
Day's Range 131.84 - 135.49
52-Week Range 113.52 - 176.73
Dividend & Yield N/A (N/A)
JAZZ Stock Predictions, Articles, and Jazz Pharma Plc News
- From InvestorPlace
- From the Web
Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.
P/B ratio is a convenient tool to identify low-priced stocks that have high-growth prospects. Here are five stocks with low P/B ratios.
These five biotech stocks balance low valuation with high growth and a track record of profits.
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects. Compare Brokers....
Jazz Pharmaceuticals stock is hovering around breakeven after agreeing to acquire Celator (CPXX) for a 73% premium. Does the deal make sense?
Was 2015 the final nail in the coffin for buy-and-hold investing? Not necessarily. Buy these 7 names and hold for 2016 before letting them go
While the rest of the market is enjoying a healthy start to the fall, biopharma stocks continue to lag. Here are 5 pharma stocks on sale now
Jazz Pharmaceuticals, bluebird bio, Illumina and Celgene are the latest batch of biotech stocks worth serious consideration.
By Jeff Reeves
The S&P has roughly doubled in the past five years, but these 10 stocks blow that performance out of the water, with gains of 1,500% or more.
Two of Jazz Pharmaceuticals' drugs are showing record growth, and the stock just keeps making new highs. Can it last?
This week, five Pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
There a number of outstanding opportunities in European stocks, as long as you can do the work to find them. Here are 5 top performers to start with now.
Wells Fargo analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed last Monday at $133.26. According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.5% and a 39.5% success rate. Maris covers the Healthcare
Analysts Offer Insights on Healthcare Companies: Electrocore Llc (NASDAQ: ECOR) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Electrocore Llc (ECOR – Research Report) and Jazz Pharmaceuticals (JAZZ – Research Report) with bullish sentiments. Electrocore Llc (ECOR) Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Electrocore Llc yesterday and set a price target
From Smarter Analyst
H.C. Wainwright analyst Oren Livnat maintained a Hold rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $147. The company’s shares closed yesterday at $136.68. Livnat said: “Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10%
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!